MilliporeSigma unveils new viral vector facility
Second Carlsbad location expected to double CDMO’s production capacity
MilliporeSigma, a life science business of Merck, has opened its second Carlsbad, CA-based facility, expanding its contract development and manufacturing organization (CDMO) footprint. According to company officials, this new $110 million, 140,000-square-foot facility will more than double MilliporeSigma’s existing capacity to support large-scale commercial and industrial manufacturing for viral gene therapy.
As mentioned earlier, this is the CDMO’s second Carlsbad facility dedicated to cell and gene therapy. There are a total of 30 cleanroom suites between both centers to support all aspects of manufacturing, ranging from small- to large-scale clinical and commercial production.
“We are continuing to invest in solving cell and gene therapy challenges in development and manufacturing, working alongside drug developers to industrialize, scale and accelerate the path to deliver therapies to patients,” notes Matthias Heinzel, member of the executive board and CEO, life science, Merck KGaA, Darmstadt, Germany.
Strategic Trends in Pharmaceutical Manufacturing for Industry Leaders
March 10th 2025This link in the pharma supply chain is undergoing a major transformation propelled by technological advancements, regulatory changes, and evolving market dynamics, requiring industry leaders to adopt innovative strategies in order to remain competitive.
